AAAAAA

   
Results: 1-25 |
Results: 25
DOSE-ESCALATION OF THE HYPOXIC CELL SENSITIZER ETANIDAZOLE COMBINED WITH IFOSFAMIDE, CARBOPLATIN, ETOPOSIDE, AND AUTOLOGOUS HEMATOPOIETIC STEM-CELL SUPPORT
Authors: ELIAS AD WHEELER C AYASH LJ SCHWARTZ G IBRAHIM J MILLS L MCCAULEY M COLEMAN N WARREN D SCHNIPPER L ANTMAN KH TEICHER BA FREI E
Citation: Ad. Elias et al., DOSE-ESCALATION OF THE HYPOXIC CELL SENSITIZER ETANIDAZOLE COMBINED WITH IFOSFAMIDE, CARBOPLATIN, ETOPOSIDE, AND AUTOLOGOUS HEMATOPOIETIC STEM-CELL SUPPORT, Clinical cancer research, 4(6), 1998, pp. 1443-1449
BREAST AND OVARIAN-CANCER PRONE WOMEN AND PROPHYLACTIC SURGERY TEMPTATION - IN REPLY
Authors: GRANN VR PANAGEAS KS ANTMAN KH WHANG W NEUGUT AI
Citation: Vr. Grann et al., BREAST AND OVARIAN-CANCER PRONE WOMEN AND PROPHYLACTIC SURGERY TEMPTATION - IN REPLY, Journal of clinical oncology, 16(7), 1998, pp. 2575-2575
DECISION-ANALYSIS OF PROPHYLACTIC MASTECTOMY AND OOPHORECTOMY IN BRCA1-POSITIVE OR BRCA2-POSITIVE PATIENTS
Authors: GRANN VR PANAGEAS KS WHANG W ANTMAN KH NEUGUT AI
Citation: Vr. Grann et al., DECISION-ANALYSIS OF PROPHYLACTIC MASTECTOMY AND OOPHORECTOMY IN BRCA1-POSITIVE OR BRCA2-POSITIVE PATIENTS, Journal of clinical oncology, 16(3), 1998, pp. 979-985
HIGH-DOSE THIOTEPA AND ETOPOSIDE-BASED REGIMENS WITH AUTOLOGOUS HEMATOPOIETIC SUPPORT FOR HIGH-RISK OR RECURRENT CNS TUMORS IN CHILDREN ANDADULTS
Authors: PAPADOPOULOS KP GARVIN JH FETELL M VAHDAT LT GARRETT TJ SAVAGE DG BALMACEDA C BRUCE J SISTI M ISAACSON S DELAPAZ R HAWKS R BAGIELLA E ANTMAN KH HESDORFFER CS
Citation: Kp. Papadopoulos et al., HIGH-DOSE THIOTEPA AND ETOPOSIDE-BASED REGIMENS WITH AUTOLOGOUS HEMATOPOIETIC SUPPORT FOR HIGH-RISK OR RECURRENT CNS TUMORS IN CHILDREN ANDADULTS, Bone marrow transplantation, 22(7), 1998, pp. 661-667
HARVEST QUALITY AND FACTORS AFFECTING COLLECTION AND ENGRAFTMENT OF CD34-CANCER SCHEDULED FOR HIGH-DOSE CHEMOTHERAPY AND PERIPHERAL-BLOOD PROGENITOR-CELL SUPPORT( CELLS IN PATIENTS WITH BREAST)
Authors: PAPADOPOULOS KP AYELLO J TUGULEA S HEITJAN DF WILLIAMS C REISS RF VAHDAT LT SUCIUFOCA N ANTMAN KH HESDORFFER CS
Citation: Kp. Papadopoulos et al., HARVEST QUALITY AND FACTORS AFFECTING COLLECTION AND ENGRAFTMENT OF CD34-CANCER SCHEDULED FOR HIGH-DOSE CHEMOTHERAPY AND PERIPHERAL-BLOOD PROGENITOR-CELL SUPPORT( CELLS IN PATIENTS WITH BREAST), Journal of hematotherapy, 6(1), 1997, pp. 61-68
HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM-CELL SUPPORT FOR BREAST-CANCER IN NORTH-AMERICA
Authors: ANTMAN KH ROWLINGS PA VAUGHAN WP PELZ CJ FAY JW FIELDS KK FREYTES CO GALE RP HILLNER BE HOLLAND HK KENNEDY MJ KLEIN JP LAZARUS HM MCCARTHY PL SAEZ R SPITZER G STADTMAUER EA WILLIAMS SF WOLFF S SOBOCINSKI KA ARMITAGE JO HOROWITZ MM
Citation: Kh. Antman et al., HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM-CELL SUPPORT FOR BREAST-CANCER IN NORTH-AMERICA, Journal of clinical oncology, 15(5), 1997, pp. 1870-1879
ADJUVANT THERAPY OF SARCOMAS OF SOFT-TISSUE
Authors: ANTMAN KH
Citation: Kh. Antman, ADJUVANT THERAPY OF SARCOMAS OF SOFT-TISSUE, Seminars in oncology, 24(5), 1997, pp. 556-560
THE ROLE OF CYTOLOGIC EVALUATION OF PLEURAL FLUID IN THE DIAGNOSIS OFMALIGNANT MESOTHELIOMA
Authors: RENSHAW AA DEAN BR ANTMAN KH SUGARBAKER DJ CIBAS ES
Citation: Aa. Renshaw et al., THE ROLE OF CYTOLOGIC EVALUATION OF PLEURAL FLUID IN THE DIAGNOSIS OFMALIGNANT MESOTHELIOMA, Chest, 111(1), 1997, pp. 106-109
INCIDENCE OF MALIGNANT PLEURAL MESOTHELIOMA AFTER THORACIC RADIOTHERAPY
Authors: NEUGUT AI AHSAN H ANTMAN KH
Citation: Ai. Neugut et al., INCIDENCE OF MALIGNANT PLEURAL MESOTHELIOMA AFTER THORACIC RADIOTHERAPY, Cancer, 80(5), 1997, pp. 948-950
DIHYDRO-5-AZACYTIDINE IN MALIGNANT MESOTHELIOMA - A PHASE-II TRIAL DEMONSTRATING ACTIVITY ACCOMPANIED BY CARDIAC TOXICITY
Authors: VOGELZANG NJ HERNDON JE CIRRINCIONE C HARMON DC ANTMAN KH CORSON JM SUZUKI Y CITRON ML GREEN MR
Citation: Nj. Vogelzang et al., DIHYDRO-5-AZACYTIDINE IN MALIGNANT MESOTHELIOMA - A PHASE-II TRIAL DEMONSTRATING ACTIVITY ACCOMPANIED BY CARDIAC TOXICITY, Cancer, 79(11), 1997, pp. 2237-2242
PACLITAXEL (P) 825 MG M(2) MAY NOT REQUIRE STEM-CELL SUPPORT/
Authors: PAPADOPOULOS KP VAHDAT LT AYELLO J REISS RF ANTMAN KH HESDORFFER CS
Citation: Kp. Papadopoulos et al., PACLITAXEL (P) 825 MG M(2) MAY NOT REQUIRE STEM-CELL SUPPORT/, Blood, 90(10), 1997, pp. 4380-4380
HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS HEMATOPOIETIC PROGENITOR-CELL SUPPORT IN PATIENTS WITH REFRACTORY OR RELAPSED LYMPHOMA
Authors: KEOHAN ML PAPADOPOULOS KP VAHDAT LH SAVAGE DS GARRETT TJ ANTMAN KH HESDORFFER CS
Citation: Ml. Keohan et al., HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS HEMATOPOIETIC PROGENITOR-CELL SUPPORT IN PATIENTS WITH REFRACTORY OR RELAPSED LYMPHOMA, Blood, 90(10), 1997, pp. 4562-4562
EFFECT OF PENCLOMEDINE (NSC-338720) ON TELOMERE FUSIONS, CHROMATIN BLEBBING, AND CELL VIABILITY WITH AND WITHOUT TELOMERASE ACTIVITY AND ABROGATED P53 FUNCTION
Authors: PANDITA TK BENVENUTO JA SHAY JW PANDITA RK RAKOVITCH E GEARD CR ANTMAN KH NEWMAN RA
Citation: Tk. Pandita et al., EFFECT OF PENCLOMEDINE (NSC-338720) ON TELOMERE FUSIONS, CHROMATIN BLEBBING, AND CELL VIABILITY WITH AND WITHOUT TELOMERASE ACTIVITY AND ABROGATED P53 FUNCTION, Biochemical pharmacology, 53(3), 1997, pp. 409-415
STATUS OF THE MEDICAL ONCOLOGY WORKFORCE
Authors: MAYER RJ ANTMAN KH BAILES JS BLOOMFIELD CD CANELLOS GP GLICK JH JACOBS CD
Citation: Rj. Mayer et al., STATUS OF THE MEDICAL ONCOLOGY WORKFORCE, Journal of clinical oncology, 14(9), 1996, pp. 2612-2621
MALIGNANT MESOTHELIOMA FOLLOWING TREATMENT FOR HODGKINS-DISEASE
Authors: WEISSMANN LB CORSON JM NEUGUT AI ANTMAN KH
Citation: Lb. Weissmann et al., MALIGNANT MESOTHELIOMA FOLLOWING TREATMENT FOR HODGKINS-DISEASE, Journal of clinical oncology, 14(7), 1996, pp. 2098-2100
CIPROFLOXACIN VERSUS TRIMETHOPRIM-SULFAMETHOXAZOLE FOR PROPHYLAXIS OFBACTERIAL-INFECTIONS IN BONE-MARROW TRANSPLANT RECIPIENTS - A RANDOMIZED, CONTROLLED TRIAL
Authors: LEW MA KEHOE K RITZ J ANTMAN KH NADLER L KALISH LA FINBERG R
Citation: Ma. Lew et al., CIPROFLOXACIN VERSUS TRIMETHOPRIM-SULFAMETHOXAZOLE FOR PROPHYLAXIS OFBACTERIAL-INFECTIONS IN BONE-MARROW TRANSPLANT RECIPIENTS - A RANDOMIZED, CONTROLLED TRIAL, Journal of clinical oncology, 13(1), 1995, pp. 239-250
PHASE-I STUDY OF HIGH-DOSE IFOSFAMIDE, CARBOPLATIN AND ETOPOSIDE WITHAUTOLOGOUS HEMATOPOIETIC STEM-CELL SUPPORT
Authors: ELIAS AD AYASH LJ WHEELER C SCHWARTZ G TEPLER I GONIN R MCCAULEY M MAZANET R SCHNIPPER L FREI E ANTMAN KH
Citation: Ad. Elias et al., PHASE-I STUDY OF HIGH-DOSE IFOSFAMIDE, CARBOPLATIN AND ETOPOSIDE WITHAUTOLOGOUS HEMATOPOIETIC STEM-CELL SUPPORT, Bone marrow transplantation, 15(3), 1995, pp. 373-379
A PROPOSED NEW INTERNATIONAL TNM STAGING SYSTEM FOR MALIGNANT PLEURALMESOTHELIOMA
Authors: AISNER J BOUTIN C BUTCHART EG CHAHINIAN P FABER LP HEELAN R MATTSON K PASS HI PATZ EF ROBINSON B RUSCH VW TAMMILEHTO L VOGELZANG NJ AISNER S ANTMAN KH BELANI CP BIGNON J BRODIN O FEINS R GINSBERG R HAMMAR S HERNDON J HILLARDEL G ILSON D KELLER S KELSEN D KRASNA M MAASILTA P MONNET I ROGGLI VL RUFFIE P SALMINEN U SALTZ L STRAUSS G VIALLAT JR VONBULTZINGSLOWEN F
Citation: J. Aisner et al., A PROPOSED NEW INTERNATIONAL TNM STAGING SYSTEM FOR MALIGNANT PLEURALMESOTHELIOMA, Chest, 108(4), 1995, pp. 1122-1128
TRIMETREXATE IN MALIGNANT MESOTHELIOMA - A CANCER AND LEUKEMIA GROUP-B PHASE-II STUDY
Authors: VOGELZANG NJ WEISSMAN LB HERNDON JE ANTMAN KH COOPER MR CORSON JM GREEN MR
Citation: Nj. Vogelzang et al., TRIMETREXATE IN MALIGNANT MESOTHELIOMA - A CANCER AND LEUKEMIA GROUP-B PHASE-II STUDY, Journal of clinical oncology, 12(7), 1994, pp. 1436-1442
PHASE-IV TRIAL OF DAILY ORAL ETOPOSIDE IN THE TREATMENT OF ADVANCED SOFT-TISSUE SARCOMA
Authors: LICHT JD MAZANET R LOEHRER PJ GONIN R ANTMAN KH
Citation: Jd. Licht et al., PHASE-IV TRIAL OF DAILY ORAL ETOPOSIDE IN THE TREATMENT OF ADVANCED SOFT-TISSUE SARCOMA, Cancer chemotherapy and pharmacology, 34(1), 1994, pp. 79-80
HIGH-DOSE IFOSFAMIDE CARBOPLATIN/ETOPOSIDE WITH AUTOLOGOUS HEMATOPOIETIC STEM-CELL SUPPORT - SAFETY AND FUTURE-DIRECTIONS/
Authors: ELIAS AD AYASH LJ WHEELER C SCHWARTZ G TEPLER I MCCAULEY M MAZANET R SCHNIPPER L FREI E ANTMAN KH
Citation: Ad. Elias et al., HIGH-DOSE IFOSFAMIDE CARBOPLATIN/ETOPOSIDE WITH AUTOLOGOUS HEMATOPOIETIC STEM-CELL SUPPORT - SAFETY AND FUTURE-DIRECTIONS/, Seminars in oncology, 21(5), 1994, pp. 83-85
HIGH-DOSE CHEMOTHERAPY IN SOLID TUMORS
Authors: ANTMAN KH SOUHAMI RL
Citation: Kh. Antman et Rl. Souhami, HIGH-DOSE CHEMOTHERAPY IN SOLID TUMORS, Annals of oncology, 4, 1993, pp. 29-44
USE OF PERIPHERAL-BLOOD PROGENITOR CELLS ABROGATES THE MYELOTOXICITY OF REPETITIVE OUTPATIENT HIGH-DOSE CARBOPLATIN AND CYCLOPHOSPHAMIDE CHEMOTHERAPY
Authors: TEPLER I CANNISTRA SA FREI E GONIN R ANDERSON KC DEMETRI G NILOFF J GOODMAN H MUNTZ H MUTO M SHEETS E ELIAS AD MAZANET R WHEELER C AYASH L SCHWARTZ G MCCAULEY M GAYNES L HARVEY S SCHNIPPER LE ANTMAN KH
Citation: I. Tepler et al., USE OF PERIPHERAL-BLOOD PROGENITOR CELLS ABROGATES THE MYELOTOXICITY OF REPETITIVE OUTPATIENT HIGH-DOSE CARBOPLATIN AND CYCLOPHOSPHAMIDE CHEMOTHERAPY, Journal of clinical oncology, 11(8), 1993, pp. 1583-1591
NODE STATUS HAS PROGNOSTIC-SIGNIFICANCE IN THE MULTIMODALITY THERAPY OF DIFFUSE, MALIGNANT MESOTHELIOMA
Authors: SUGARBAKER DJ STRAUSS GM LYNCH TJ RICHARDS W MENTZER SJ LEE TH CORSON JM ANTMAN KH
Citation: Dj. Sugarbaker et al., NODE STATUS HAS PROGNOSTIC-SIGNIFICANCE IN THE MULTIMODALITY THERAPY OF DIFFUSE, MALIGNANT MESOTHELIOMA, Journal of clinical oncology, 11(6), 1993, pp. 1172-1178
SELECTED BENEFITS OF THORACOTOMY AND CHEMOTHERAPY FOR SARCOMA METASTATIC TO THE LUNG
Authors: MENTZER SJ ANTMAN KH ATTINGER C SHEMIN R CORSON JM SUGARBAKER DJ
Citation: Sj. Mentzer et al., SELECTED BENEFITS OF THORACOTOMY AND CHEMOTHERAPY FOR SARCOMA METASTATIC TO THE LUNG, Journal of surgical oncology, 53(1), 1993, pp. 54-59
Risultati: 1-25 |